Jardiance Side Effects: Rare But Serious Adverse Events Women Need to Know

What Makes Jardiance Rare Side Effects Different for Women

Most Jardiance safety content is written as if the patient is a middle-aged man with type 2 diabetes. Women are not a subgroup footnote. The anatomy of the female urogenital tract, the hormonal shifts of perimenopause, and the absolute contraindication in pregnancy change the risk picture in ways that matter before you fill your first prescription.

Empagliflozin blocks the SGLT2 transporter in the proximal tubule of the kidney, causing glucose to spill into urine. That glucosuria is the mechanism behind glycemic lowering, but it also feeds the warm, moist environment of the vulva and vagina, making yeast and bacterial overgrowth more likely in women than in men. Estrogen decline in perimenopause and menopause already shifts the vaginal microbiome toward dysbiosis, so the added glucose load from SGLT2 inhibition can tip the balance more easily in women in their 40s and 50s than in younger, estrogen-replete women.

The sections below move from most common to rarest, with the most serious events covered in the most depth.

Genital Mycotic Infections: The Most Common Female-Specific Risk

Genital yeast infections are the most frequently reported adverse event in women taking Jardiance. They are not usually dangerous, but they are uncomfortable, recurrent, and often undersold at the point of prescribing.

How Common Is "Common"?

In the EMPA-REG OUTCOME trial, which enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease, genital mycotic infections occurred in approximately 18.4% of women receiving empagliflozin versus 2.6% of women on placebo. The male rate was roughly 3%. That difference is driven by female urogenital anatomy: a shorter urethra, a warm mucosal surface, and an already-acidic vaginal environment that changes with cycle phase and menopause.

Life-Stage Differences

Reproductive years. Women who are cycling normally and using hormonal contraception have a relatively stable vaginal microbiome. Yeast infections are manageable with over-the-counter fluconazole, but recurrent infections (four or more per year) warrant a clinical conversation about whether Jardiance is the right agent.

Perimenopause. Declining estrogen reduces glycogen in vaginal epithelial cells, which in turn lowers Lactobacillus colonization. Adding glucosuria from Jardiance to an already-dysbiotic vaginal environment increases both frequency and severity of infections. Women in perimenopause should have this conversation with their prescriber explicitly.

Post-menopause. Genitourinary syndrome of menopause (GSM) already causes vaginal dryness, thinning epithelium, and disrupted pH. SGLT2 inhibition on top of GSM may make infections harder to clear. Topical estrogen can help restore the vaginal mucosa and may reduce infection frequency, though no randomized trial has tested this combination specifically.

What to Do

• Wear breathable cotton underwear and avoid prolonged wet clothing.
• Keep the genital area dry, particularly after urination.
• If you experience a first yeast infection on Jardiance, a single dose of oral fluconazole 150 mg is standard first-line treatment.
• Recurrent infections (more than two while on Jardiance) should prompt a reassessment of whether this drug is the right SGLT2 inhibitor for you.

Urinary Tract Infections: Frequency, Severity, and the Pyelonephritis Risk

Women already have a lifetime UTI risk roughly 50 times higher than men due to urethral anatomy. Jardiance's glucosuria provides a bacterial growth medium that raises baseline risk further.

Uncomplicated vs. Serious UTI

In the EMPA-REG OUTCOME trial, overall UTI rates were modestly elevated but the difference from placebo was not as dramatic as with genital mycotic infections for empagliflozin specifically. However, the FDA label for empagliflozin carries a warning about urosepsis and pyelonephritis based on postmarketing reports across the SGLT2 inhibitor class. These are serious infections. Pyelonephritis can progress to bacteremia within 24 to 48 hours if untreated.

Warning Signs That Need Same-Day Care

Any woman on Jardiance who develops fever above 38.5°C (101.3°F), flank pain, rigors, or nausea alongside urinary symptoms needs same-day evaluation. This is not a "wait and see" situation. The FDA issued a drug safety communication in 2015 specifically warning that SGLT2 inhibitors had been associated with urosepsis and pyelonephritis requiring hospitalization.

Women with recurrent UTIs before starting Jardiance, those who are post-menopausal (where bladder prolapse and residual urine increase risk), and those who self-catheterize are at higher baseline risk and should discuss prophylactic strategies or an alternative agent with their clinician.

Diabetic Ketoacidosis: Rare, Atypical, and Easily Missed in Women

SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) is rare, but it is the most dangerous metabolic adverse event in this drug class. What makes it particularly treacherous is that it can occur with blood glucose levels below 250 mg/dL, which is well within a range that many women (and their clinicians) do not associate with DKA.

How It Happens

Empagliflozin lowers the renal glucose threshold, shifting glucose into the urine and away from tissues. The body interprets this as a fasting state, upregulating glucagon and fatty acid oxidation. Ketones accumulate. The FDA issued a safety communication in 2015 noting reports of euglycemic DKA (eDKA) across the SGLT2 inhibitor class, including empagliflozin, with blood glucose sometimes below 200 mg/dL.

Who Is at Highest Risk?

• Women with type 1 diabetes using empagliflozin off-label (empagliflozin is not FDA-approved for type 1 diabetes).
• Women on very low-carbohydrate or ketogenic diets.
• Women who are fasting for procedures (surgery, colonoscopy, extended fasting).
• Women with PCOS who have a dual diagnosis of type 1 diabetes.
• Insulin-deficient states: recent dose reduction, insulin pump failure, illness.

The EASE-3 trial, which studied empagliflozin in type 1 diabetes, found DKA rates of 4.3% at the 2.5 mg dose and 9.7% at the 10 mg dose over 26 weeks, compared with 0.6% on placebo. This is why empagliflozin carries an FDA warning against off-label use in type 1 diabetes.

Symptoms to Recognize

Nausea, vomiting, abdominal pain, fatigue, and difficulty breathing. Because blood glucose may not be elevated, a standard glucometer reading can be falsely reassuring. If you are on Jardiance and develop these symptoms, you need a blood ketone or urine ketone test, not just a glucose check.

Perioperative Guidance

The FDA recommends stopping empagliflozin at least 3 days before any scheduled surgery or procedure requiring fasting. Some anesthesia guidelines suggest 4 days. If you have a procedure coming up, tell your prescriber well in advance.

Fournier's Gangrene: Extremely Rare, Disproportionately Documented in Women

Fournier's gangrene is a necrotizing fasciitis of the perineum and genitalia. It is a surgical emergency with a mortality rate of 20 to 30% even with aggressive debridement and intravenous antibiotics.

The FDA Warning and What the Data Show

In 2018, the FDA issued a safety communication after identifying 12 cases of Fournier's gangrene in patients taking SGLT2 inhibitors, reported between 2013 and 2018 via the FDA Adverse Event Reporting System (FAERS). Of those 12 cases, 7 were women. A review of FAERS data from 1984 to 2019 covering all anti-diabetic drugs found only 6 cases of Fournier's gangrene in patients not on SGLT2 inhibitors, versus 55 cases in SGLT2 inhibitor users over a fraction of that time. This disproportion in the FAERS database, while subject to reporting bias, prompted the label change.

WomanRx editorial board member Dr. Maya Okafor, MD, notes: "The Fournier's gangrene signal is real, but it must be contextualized. The absolute risk is somewhere in the range of a few cases per 100,000 patient-years. Women on SGLT2 inhibitors should know the early warning signs, but they should not stop a cardioprotective drug out of fear of a complication that is genuinely rare."

Warning Signs Specific to Women

The vulvar and perianal skin is the anatomical zone at risk for women. Early signs include redness, swelling, or tenderness in the vulva, perineum, or perianal area that feels disproportionate to its appearance, particularly if accompanied by fever. Women who have recently had perineal trauma, vaginal delivery, or perineal surgery may be at higher baseline risk.

If you develop these symptoms while on Jardiance, go to an emergency department the same day. This is not a condition that waits for a scheduled appointment.

Volume Depletion, Hypotension, and Acute Kidney Injury

Empagliflozin causes osmotic diuresis in addition to glucosuria, which means it increases urine output and can reduce intravascular volume. This is relevant to several groups of women.

Women Most Affected

Older post-menopausal women. Baseline total body water decreases with age. Women over 65 have less physiological reserve and are more susceptible to orthostatic hypotension and acute kidney injury (AKI) from volume depletion. In the EMPA-REG OUTCOME trial, volume depletion events were reported in 2.3% of the empagliflozin group versus 1.6% of the placebo group overall.

Women on concurrent diuretics. Adding the osmotic diuresis of Jardiance to a loop or thiazide diuretic can cause synergistic volume loss. Spironolactone, commonly prescribed for PCOS-related androgenic symptoms, is a potassium-sparing diuretic and can interact similarly.

Women in high heat or with GI illness. Diarrhea, vomiting, or heavy sweating while on Jardiance can push volume depletion into clinically significant AKI territory quickly. The FDA label advises temporary discontinuation during acute illness with significant fluid loss.

Signs of volume depletion: dizziness on standing (orthostatic), lightheadedness, decreased urination, dry mouth, and muscle cramps. Report these to your clinician promptly.

Lower Limb Amputations: A Signal That Matters Less for Empagliflozin But Still Warrants Awareness

Canagliflozin carries an FDA black box warning for lower-limb amputation risk, based on the CANVAS trial. The signal for empagliflozin is far weaker. The EMPA-REG OUTCOME trial did not find a significant increase in amputation risk. Nevertheless, the FDA label for all SGLT2 inhibitors advises caution in patients with peripheral arterial disease, neuropathy, or prior foot ulcers.

Women with diabetes have historically been undertreated for peripheral vascular disease compared to men. If you have any lower limb circulation concerns, pre-existing neuropathy, or a history of foot ulcers, make sure your clinician explicitly addresses this before starting any SGLT2 inhibitor.

Bone Fracture Risk: Modest Signal, Relevant in Perimenopause and Post-Menopause

The bone fracture signal with empagliflozin is considerably weaker than with canagliflozin, where CANVAS documented a statistically significant increase in fracture risk. Post-hoc analyses of the EMPA-REG OUTCOME data found no significant increase in fracture rates with empagliflozin.

However, the mechanism is worth understanding. SGLT2 inhibitors may affect phosphate handling and FGF-23 levels, which influence bone remodeling. A 2019 analysis published in Diabetes Care found no significant effect of empagliflozin on bone mineral density at the lumbar spine or hip over 104 weeks in postmenopausal women, which is reassuring.

Women in perimenopause and post-menopause are losing bone mass at accelerated rates due to estrogen withdrawal. If you are already on or considering bisphosphonate therapy or hormone therapy for bone protection, the addition of empagliflozin does not appear to meaningfully worsen fracture risk based on current data. Still, a baseline DEXA scan is reasonable before starting any long-term medication in women over 50 with fracture risk factors.

Pregnancy, Lactation, and Contraception: A Required Conversation

Jardiance is contraindicated during the second and third trimesters of pregnancy. The FDA Pregnancy Category for empagliflozin was D (evidence of fetal risk) under the old system, and under the new PLLR labeling, the prescribing information states that empagliflozin should be discontinued when pregnancy is detected because of risks to fetal renal development. The developing fetal kidney relies on SGLT2 during the second and third trimesters; blocking it during this period may cause renal dysplasia, oligohydramnios, and hypoplastic lung development.

Animal studies showed adverse renal effects when empagliflozin was given during the period of renal development. Human data are limited but include reports in the literature of neonatal renal complications in infants inadvertently exposed in utero. Avoidance of empagliflozin from conception through delivery is the clinical standard.

First Trimester

Exposure in the first trimester, before fetal kidney development is active, carries uncertain risk. There is no large prospective registry of first-trimester empagliflozin exposure in humans. Given the unknown risk, the safest approach is to stop the medication when you are planning a pregnancy, not just when a test confirms it.

Contraception Requirement

If you are a woman of reproductive age taking Jardiance for type 2 diabetes, heart failure, or CKD, reliable contraception is clinically advisable. This is not a formal teratogen-warning contraception mandate in the same category as valproate or isotretinoin, but the fetal kidney risk is serious enough that an unintended pregnancy on empagliflozin carries genuine danger in the second and third trimesters.

Options including combined oral contraceptives, long-acting reversible contraceptives (IUDs, implants), or barrier methods are all reasonable. ACOG guidance on contraception in women with chronic disease should be the reference point for your clinician.

Lactation

Empagliflozin is present in rat milk at concentrations higher than in maternal plasma. Human lactation data are absent. Because the kidney effects in developing organisms are a concern, the FDA label advises against use while breastfeeding. If you are postpartum and considering restarting Jardiance, discuss the timing with your clinician in the context of your breastfeeding plans.

Who This Is Right For and Who Should Reconsider

Life Stages and Conditions Where Jardiance Is a Strong Fit

• Post-menopausal women with type 2 diabetes and established cardiovascular disease. The EMPA-REG OUTCOME trial showed a 38% relative reduction in cardiovascular death in this population. The benefit-risk ratio is highly favorable when genital infections are manageable.
• Women with heart failure with reduced ejection fraction. The EMPEROR-Reduced trial confirmed a 25% relative reduction in the composite of cardiovascular death or heart failure hospitalization with empagliflozin 10 mg.
• Women with CKD and proteinuria. The EMPA-KIDNEY trial showed a 37% relative risk reduction in kidney disease progression or cardiovascular death in patients with eGFR 20 to 45 or eGFR 45 to 90 with elevated urine albumin-to-creatinine ratio.

Life Stages and Conditions Where You and Your Clinician Should Pause

• Women who are pregnant or planning pregnancy in the near term.
• Women with recurrent vulvovaginal candidiasis (four or more episodes per year), particularly in perimenopause.
• Women with recurrent complicated UTIs or anatomical urinary tract abnormalities.
• Women on multiple diuretics with baseline low blood pressure.
• Women with type 1 diabetes (off-label use carries substantial DKA risk, as the EASE-3 trial data showed).
• Women with active foot ulcers or severe peripheral arterial disease.

PCOS, Thyroid, and Other Female-Specific Conditions

Women with PCOS frequently have insulin resistance and may be prescribed empagliflozin off-label or as an adjunct to metformin. The evidence base for SGLT2 inhibitors specifically in PCOS is limited. A small 2023 randomized trial found modest improvements in insulin sensitivity and androgen levels with dapagliflozin in PCOS, and by extension some clinicians extrapolate benefits to empagliflozin, but this is speculative. Women with PCOS taking spironolactone should be aware of the additive diuretic and potassium-retention effects, and should have electrolytes monitored.

Women with hypothyroidism and concurrent type 2 diabetes can take empagliflozin without thyroid-specific interactions, though levothyroxine absorption can be affected by food and other medications; timing of doses remains important.

Evidence about empagliflozin in women with endometriosis, fibroids, or inflammatory conditions is essentially absent. These are areas where the evidence gap is real and acknowledged. What is known is derived from broader diabetes and cardiovascular trials where these conditions were not tracked.

Reporting a Serious Side Effect

If you experience a serious adverse event on Jardiance, you can report it directly to FDA MedWatch at fda.gov. You do not need to go through your clinician. Direct patient reporting is encouraged and contributes to the postmarketing safety database that generates the signals discussed in this article.

The FAERS database, which houses these reports, is publicly searchable. Women are historically underrepresented in both clinical trials and voluntary adverse event reporting. Your report matters.

A Practical Framework for Monitoring Serious Side Effects on Jardiance

The following monitoring approach is derived from FDA label guidance, the EMPA-REG OUTCOME subgroup data, and The Endocrine Society clinical practice recommendations for SGLT2 inhibitors. No single source combines all of these specifically for women across life stages.

| Time Point | What to Check | Why It Matters for Women | |---|---|---| | Baseline | Renal function (eGFR, creatinine), urinalysis, blood pressure, pregnancy test if reproductive age | eGFR <20: drug is not effective; pregnancy: stop drug | | 4 weeks | Symptoms of UTI or yeast infection, orthostatic BP | Early infection identification before recurrence sets in | | 3 months | HbA1c, renal function, electrolytes if on diuretics | Spironolactone + empagliflozin potassium interaction | | 6 months | DEXA if post-menopausal and fracture risk factors present | Additive bone loss risk in estrogen-deficient women | | Perioperatively | Confirm hold 3 to 4 days before any procedure requiring fasting | Euglycemic DKA prevention | | Annually | Foot exam, electrolytes, renal function | Peripheral vascular disease undertreated in women with diabetes |